Lenalidomide in multiple myeloma

Abstract

Treatment options for patients have increased over the last few years, especially with the availability of novel agents for routine care and within clinical trials. Owing to the promising activity seen with lenalidomide in the relapsed/refractory setting, its use has now expanded to induction and maintenance therapy. It is generally well tolerated and the side effects, including hematological toxicity and thromboembolic complications, are usually easily managed. Although new treatments including lenalidomide have increased response rates, the survival has not been strongly impacted. This article will summarize recent data and ongoing clinical trials.

Keywords::

• lenalidomide
• multiple myeloma
• targeted therapy

Financial & competing interests disclosure

Ray Powles is on the advisory board for Kyowa Hakko Kirin. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.